相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA)
M. Sznol et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase II study of bavituximab plus paclitaxel and carboplatin in untreated locally advanced or metastatic non-small cell lung cancer: Interim results.
R. Digumarti et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
M. Reck et al.
ANNALS OF ONCOLOGY (2013)
AMP-224, A FUSION PROTEIN THAT TARGETS PD-1
F. Smothers et al.
ANNALS OF ONCOLOGY (2013)
Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
Evan J. Lipson et al.
CLINICAL CANCER RESEARCH (2013)
Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response
Cheng Chen et al.
EXPERIMENTAL CELL RESEARCH (2013)
Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial
Hubert Serve et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Reciprocal Relationship between Myeloid-Derived Suppressor Cells and T Cells
Srinivas Nagaraj et al.
JOURNAL OF IMMUNOLOGY (2013)
Prognostic implications of human leukocyte antigen class I expression in patients who underwent surgical resection for non-small-cell lung cancer
Takeshi Hanagiri et al.
JOURNAL OF SURGICAL RESEARCH (2013)
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
Luana Calabro et al.
LANCET ONCOLOGY (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Phosphatidylserine-Targeting Antibody Induces M1 Macrophage Polarization and Promotes Myeloid-Derived Suppressor Cell Differentiation
Yi Yin et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Involvement of STAT3 in immune evasion during lung tumorigenesis
Hiroshi Kida et al.
ONCOIMMUNOLOGY (2013)
PD-L1 gene expression in Japanese lung cancer patients
Hidefumi Sasaki et al.
BIOMEDICAL REPORTS (2013)
Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer
Hui Liu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Monocytic CCR2+ Myeloid-Derived Suppressor Cells Promote Immune Escape by Limiting Activated CD8 T-cell Infiltration into the Tumor Microenvironment
Alexander M. Lesokhin et al.
CANCER RESEARCH (2012)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
New Challenges in Endpoints for Drug Development in Advanced Melanoma
Antoni Ribas et al.
CLINICAL CANCER RESEARCH (2012)
Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer
Carlo Genova et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
KIR2DL2/S2 and HLA-C C1C1 genotype is associated with better response to treatment and prolonged survival of patients with non-small cell lung cancer in a Polish Caucasian population
Andrzej Wisniewski et al.
HUMAN IMMUNOLOGY (2012)
High transforming growth factor β expression represents an important prognostic parameter for surgically resected non-small cell lung cancer
William Sterlacci et al.
HUMAN PATHOLOGY (2012)
Interleukin-27 Priming of T Cells Controls IL-17 Production In trans via Induction of the Ligand PD-L1
Kiyoshi Hirahara et al.
IMMUNITY (2012)
Increased numbers but functional defects of CD56+CD3+ cells in lung cancer
Suliman Y. Al Omar et al.
INTERNATIONAL IMMUNOLOGY (2012)
Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors
Helene Salmon et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs
Saroj Niraula et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The Challenge and Promise of the Genomic Era
George W. Sledge
JOURNAL OF CLINICAL ONCOLOGY (2012)
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
Thomas J. Lynch et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
B7-DC-Ig Enhances Vaccine Effect by a Novel Mechanism Dependent on PD-1 Expression Level on T Cell Subsets
Mikayel Mkrtichyan et al.
JOURNAL OF IMMUNOLOGY (2012)
Impact of Collection and Storage of Lung Tumor Tissue on Whole Genome Expression Profiling
Maxim B. Freidin et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2012)
When Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for Progression
Geoffrey R. Oxnard et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy
Alexander Drilon et al.
LANCET ONCOLOGY (2012)
Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC)
Nasrollah Erfani et al.
LUNG CANCER (2012)
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Hirokazu Matsushita et al.
NATURE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Within tumors, interactions between T cells and tumor cells are impeded by the extracellular matrix
Helene Salmon et al.
ONCOIMMUNOLOGY (2012)
Phase I Safety and Pharmacokinetic Study of Bavituximab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients with Advanced Solid Tumors
David E. Gerber et al.
CLINICAL CANCER RESEARCH (2011)
Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms
Mikayel Mkrtichyan et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
PD-L1 expression on tolerogenic APCs is controlled by STAT-3
Sabine J. Woelfle et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
Increased killer immunoglobulin-like receptor expression and functional defects in natural killer cells in lung cancer
Suliman Y. Al Omar et al.
IMMUNOLOGY (2011)
Addition of Bevacizumab to Chemotherapy for Treatment of Solid Tumors: Similar Results but Different Conclusions
Alberto Ocana et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice
Taku Okazaki et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Non-small Cell Lung Cancer Induces an Immunosuppressive Phenotype of Dendritic Cells in Tumor Microenvironment by Upregulating B7-H3
Thomas Schneider et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Delivering affordable cancer care in high-income countries
Richard Sullivan et al.
LANCET ONCOLOGY (2011)
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
Alice T. Shaw et al.
LANCET ONCOLOGY (2011)
6thAnnual European Antibody Congress 2010
Alain Beck et al.
mAbs (2011)
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation
Chuan-Yong Mu et al.
MEDICAL ONCOLOGY (2011)
NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation
Andreas T. Bjorklund et al.
BLOOD (2010)
Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer
Yan Zhang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2010)
Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with solid tumors
Suliman Al Omar et al.
HUMAN IMMUNOLOGY (2010)
Clinical relevance and functional implications for human leucocyte antigen-g expression in non-small-cell lung cancer
A. Lin et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2010)
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
Junko Matsuzaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer
Hester van Cruijsen et al.
BMC CANCER (2009)
The Prevalence of FOXP3+ Regulatory T-Cells in Peripheral Blood of Patients with NSCLC
Liu Li et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2009)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Diagnosis value of serum B7-H3 expression in non-small cell lung cancer
Guangbo Zhang et al.
LUNG CANCER (2009)
Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56BrightCD16- cells and display an impaired capability to kill tumor cells
Paolo Carrega et al.
CANCER (2008)
Alteration of the immunological synapse in lung cancer:: a microenvironmental approach
S. Derniame et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2008)
Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures
Marie-Caroline Dieu-Nosjean et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status
Delphine Sauce et al.
AIDS (2007)
4IgB7-H3 is the major isoform expressed on immunocytes as well as malignant cells
Y.-H. Zhou et al.
TISSUE ANTIGENS (2007)
Anti-OX40 (CD134) administration to nonhuman primates: Immunostimulatory effects and toxicokinetic study
Andrew D. Weinberg et al.
JOURNAL OF IMMUNOTHERAPY (2006)
PD-L1 is induced in hepatocytes by viral infection and by interferon-α and -γ and mediates T cell apoptosis
Marcus Muehlbauer et al.
JOURNAL OF HEPATOLOGY (2006)
B7-H3 and B7-H4 expression in non-small-cell lung cancer
Yuping Sun et al.
LUNG CANCER (2006)
Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival?
N Ramnath et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
No evidence for dualism in function and receptors:: PD-L2/B7-DC is an inhibitory regulator of human T cell activation
Katharina Pfistershammer et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2006)
Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression:: effect over CD4 expression on T cells
J de Leòn et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
B7-h1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression
J Konishi et al.
CLINICAL CANCER RESEARCH (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Functional and molecular characterization of a KIR3DL2/p140 expressing tumor-specific cytotoxic T lymphocyte clone infiltrating a human lung carcinoma
G Dorothée et al.
ONCOGENE (2003)
Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses
SC Liang et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction
SD Wang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: Attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses
F Bennett et al.
JOURNAL OF IMMUNOLOGY (2003)
Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation
EY Woo et al.
JOURNAL OF IMMUNOLOGY (2002)
分享论文
